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Abstract 
 
Background: Volumetric mammographic density (VMD) measures can be obtained 
automatically, but it is not clear how these relate to breast cancer risk factors. 
 
Materials and methods: The cohort consisted of 46 428 women (aged 49-71 years) who 
participated in BreastScreen Norway between 2007 and 2014 and had information on VMD 
and breast cancer risk factors. We estimated means of percent and absolute VMD associated 
with age, menopausal status, body mass index (BMI), and other factors.  
 
Results: The associations between VMD and most breast cancer risk factors were modest, 
although highly significant. BMI was positively associated with absolute VMD, while 
inversely associated with percent VMD. Percent VMD was inversely associated with a five-
years older age at screening in premenopausal and postmenopausal women (-0.18% versus -
0.08% for percent VMD and -0.11 cm³ versus -0.03 cm³ for absolute VMD). This difference 
was largest among postmenopausal women with BMI<25 kg/m² (p for interaction with 
percent VMD<0.0001), never users of postmenopausal hormone therapy (p for 
interaction<0.0001), and premenopausal women with a family history of breast cancer (p for 
interaction with absolute VMD=0.054). 
 
Conclusions: VMD is associated with several breast cancer risk factors, the strongest being 
BMI, where the direction of the association differ for percent and absolute VMD. The inverse 
association with age appears modified by menopausal status and other breast cancer risk 
factors.  
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Impact: Since VMD methods are becoming widely available in screening and clinical 
settings, the association between VMD measures and breast cancer risk factors should be 
investigated further in longitudinal studies. 
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Introduction 
 
Mammographic density describes the relative amounts of radio-lucent fatty tissue versus 
radio-dense fibroglandular tissue in the breast (1). High density is a strong independent risk 
factor for breast cancer, with risk increasing with increasing density (2, 3). Women with a 
very high percentage of the breast occupied by dense tissue have a 4-6 fold increased risk of 
breast cancer compared to women who have predominately fatty breasts (3).  
Traditionally, mammographic density assessment methods are based on a two-
dimensional area-based projection of the breast. Such methods estimate area-based absolute 
density (i.e. the area occupied by dense tissue in cm
2
) as well as percent density (i.e. the 
percentage of the total breast area occupied by dense tissue). Although the latter is the most 
frequently used area-based measure of mammographic density, both percent density and 
absolute density have been shown to be strong risk factors for breast cancer (4-9). The breast 
imaging reporting and data system (BI-RADS) is a commonly used ordinal density scale 
which provides a standardized classification for mammographic density (10). 
Several automated methods have been developed for assessment of volumetric 
mammographic density (VMD) on digital images during the last decade. These methods 
assess the breast volume by multiplying the breast area on a two-dimensional mammogram by 
the compressed thickness of the breast. They determine the amount of dense tissue in the 
breast, absolute density, by integration of the thickness of dense tissue at each pixel over the 
mammogram. Percent VMD is obtained from the ratio absolute VMD divided by breast 
volume. VMD measures have produced reasonably strong associations with breast cancer risk 
when validated against visual assessment and computer-assisted methods (11). As VMD 
methods are becoming increasingly used in epidemiological studies of density (12-18) it 
becomes important to understand not only how VMD measures are associated to breast cancer 
risk, but also how they relate to established breast cancer risk factors.  
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We have much knowledge on the association between breast cancer risk factors and 
area-based mammographic density measures. Such measures of mammographic density are 
positively associated with late age at first birth, nulliparity, and postmenopausal hormone 
therapy (19-22). Alcohol intake has also been positively associated with mammographic 
density in area-based studies, while physical activity and smoking has been inversely or not 
associated (23-25). Body mass index (BMI) is strongly inversely associated with percent 
mammographic density (16), however the association with absolute mammographic density is 
less clear, with an inverse association mostly reported (6, 16, 26).  
To what extent these breast cancer risk factors affect similarly absolute and percent 
VMD is less clear. There is also less understanding of how the magnitude of VMD differs 
between women with different risk factor profiles. While a 5% arithmetic difference in 
percent density in area-based studies is indicative of an effect similar to that of 
postmenopausal hormone therapy (27), it is not yet clear what represents a “large” effect on 
VMD.  
Area-based measures have shown that mammographic density declines with 
increasing age and during the menopausal transition (28, 29). It is, however, less clear 
whether similar age- and menopause-related declines occur with VMD and, if so, which 
factors may modify the rate of such declines. 
We decided to take advantage of a large collection of VMD measures from women 
participating in BreastScreen Norway to better understand how volumetric and area-based 
mammographic density measures are correlated, how various risk factors are associated with 
both percent and absolute VMD, and the extent to which those risk factors modify age- and 
menopause-related differences. 
 
 
Materials and methods 
on June 28, 2018. © 2018 American Association for Cancer Research. cebp.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on June 20, 2018; DOI: 10.1158/1055-9965.EPI-18-0151 
 Study population 
BreastScreen Norway (the Norwegian screening program for breast cancer) is administered by 
the Cancer Registry of Norway and invites women within a targeted age-range of 50-69 years 
to a bilateral two-view mammogram biennially. It has a participation rate of about 84% (30). 
From August 2006 women who underwent mammographic screening were asked to complete 
a questionnaire on a number of standard breast cancer risk factors and a second questionnaire 
on current exposures to risk factors. At subsequent screenings they were asked to complete 
only the second questionnaire (31). Our cohort consisted of women who participated in 
BreastScreen Norway in the four counties where VMD measures were registered (Hordaland, 
Rogaland, Akershus, and Trøndelag), who had information on VMD from their first 
mammographic screening between 2007 and 2014, and had completed both questionnaires 
(n=63 544). We excluded 1194 women who had a diagnosis of breast cancer or ductal 
carcinoma in situ (DCIS) previous or up to six months after the screening date, and 622 
women who had incomplete data on the VMD variables, leaving information from a total of 
61 728 women. Further, we excluded the following due to missing information on the 
confounding variables BMI (n=6785), education (n=1425), menopausal status (n=1595), and 
number of pregnancies (n=5689). This left us with 46 234 women for analyses. In analyses of 
associations between age, menopausal status, and breast cancer risk factors, we excluded 
pre/perimenopausal women above the age of 55 years, leaving 45 448 women for these 
analyses. 
The study was approved by the Regional Committee for Medical and Health Research 
Ethics in the South-East Health Region of Norway.  
 
Mammographic density measures 
All women in the study had standard two-view (mediolateral oblique and craniocaudal) full-
field mammography of each breast with Senographe DS or Senographe Essential machines 
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(GE Healthcare) in Hordaland and Rogaland, MDM L50 (Philips) in Akershus and MDM L30 
(Philips) in Trøndelag. VMD was read using the fully automated system Volpara v1.5.0 
(Volpara Health Technologies Limited, Wellington, New Zealand). Volpara is shown to be 
associated with BI-RADS (i.e. in a study by van der Waal et al., BI-RADS category A [fatty] 
is equivalent to a median dense volume of 3.6%, category B [scattered density] 5.3%, 
category C [heterogeneously dense] 10.2%, and category D [extremely dense] 19.3%) (32).  
Volpara computes the thickness of dense tissue at each individual pixel in the mammogram, 
using a fatty region as an internal reference. To do the calculation, it is assumed that the pixel 
value is linearly related to the energy imparted to the x-ray detector, so that the difference in 
the pixel values between each pixel and the reference point can be related directly to the 
thickness of dense tissue between the pixel and the x-ray source. Absolute VMD (cm³) is 
estimated by integrating the dense thickness at each pixel over the whole mammogram and 
multiplying by the known pixel size. The total breast volume (cm³) is derived by multiplying 
the breast area (cm²) by breast thickness with a correction for the breast edge. Percent VMD 
(%) is obtained from the ratio of these two measures (33). In the analyses, we have used the 
mean VMD from both breasts of the mediolateral oblique view and of the craniocaudal view. 
Correlation between measures across breasts and views were high, r>0.89, p<0.0001 for 
percent VMD and r>0.82, p<0.0001 for absolute VMD. The main reason for using the 
average value across the four images is to reduce random measurement errors and hence to 
increase precision.  
 
Exposure information 
The breast cancer risk factors of interest included reproductive factors (age at menarche, age 
at first birth, number of pregnancies lasting at least six months, and duration of 
breastfeeding), menopausal status (whether a woman still had her menstrual period or whether 
she menstruated regularly, yes=premenopausal, uncertain=perimenopausal, 
no=postmenopausal), age at menopause (the age at which her menstrual periods stopped), and 
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hormone use (oral contraceptives and postmenopausal hormone therapy). We also examined 
self-reported height and BMI (kg/m²) at the time of the mammography, and other risk factors 
such as education (no education/primary school, high school, university bachelor, university 
master), current physical activity (no exercise, 1-2.5 hours/week, 2.5-4.5 hours/week, 4.5-6 
hours/week, >6 hours/week), alcohol intake (never, 1 glass/week, 2 glasses/week, 3-4 
glasses/week, 5-6 glasses/week, >6 glasses/week), and smoking habits (never, past, current). 
Women with a family history of breast cancer had answered “yes” to the question ‘Have your 
mother/sister/daughter had breast cancer (yes, no, do not know)’ and/or “yes” to the question 
‘Have your grandmother or your mother’s sister had breast cancer (yes, no, do not know)’. 
Information on current exposures was collected from the questionnaire belonging to the 
screening round from which we have density measures, and if the questionnaire or certain 
values were missing, information from the questionnaire completed at a previous screening 
round was used (approximately 16.5%).  
 
Statistical analyses 
We evaluated the agreement by side (left vs right) and view (mediolateral oblique vs 
craniocaudal) in correlation analyses, calculating Pearson correlation coefficients. We 
estimated marginal means of percent and absolute VMD associated with the above-mentioned 
breast cancer risk factors using generalized linear models (GLM) with the post-estimation 
Stata-command –margins- (34), with a normal error distribution and a log link, to account for 
the skewed distribution of percent and absolute VMD. We further applied robust standard 
errors to account for additional under- or overdispersion and relax the assumption of log-
normality. The delta method was used to calculate 95% confidence intervals (CI) (35). Effects 
are presented in actual percentage units for percent VMD and in cm³ for absolute VMD, in 
marginal means as predicted from the model. Based on a priori information from area-based 
studies, as well as based on trends and effect estimates observed in our analyses, we included 
the following variables as potential confounders; age at screening, BMI at screening, 
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education, number of pregnancies, and menopausal status. In additional analyses, we adjusted 
for age at menarche, age at first birth, duration of breastfeeding in months, use of 
postmenopausal hormone therapy, and family history of breast cancer. We also mutually 
adjusted for smoking, alcohol, and physical activity in analyses with those variables. Women 
with missing information on an exposure variable were excluded from analyses including that 
variable. Tests for trend were conducted by modelling the exposures as continuous variables.  
We estimated differences in percent and absolute VMD per a five-year increment in 
age at screening in pre/perimenopausal and postmenopausal women separately, overall and by 
subgroups of breast cancer risk factors. We also included an interaction term of menopausal 
status and age and tested if interaction was present using the Wald test. If an interaction was 
present, we estimated means of percent and absolute VMD per a two-year increment in age 
stratified by the breast cancer risk factor. We examined whether a non-linear model (i.e. cubic 
spline regression with five degrees of freedom) of VMD with age was a better fit than the 
linear model and compared the two models using a likelihood-ratio test. Analyses were 
carried out using Stata version 15 (36). 
 
 
Results 
 
The characteristics of the women in the study cohort are summarized in Table 1. Their mean 
age was 56.1 years, and their mean BMI was 25.6 kg/m². 73.5% of the women reported to be 
postmenopausal, and their mean age at menopause was 49.1 years. 33.5% of the women were 
ever users of postmenopausal hormone therapy, 79.2% current alcohol consumers, 23.1% 
current smokers, and 11.5% currently physically inactive. Crude (unadjusted for BMI and 
other factors) mean percent VMD was 7.2% and absolute VMD 49.3 cm³.  
Table 2 shows a strong and inverse association between BMI and percent VMD, with 
women with BMI<20 kg/m² having on average a threefold higher percent VMD than those 
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with BMI>33 kg/m² (12.9% [95% CI 12.7%–13.2%] versus 3.9% [95% CI 3.9%–4.0%]). In 
contrast, BMI was positively associated with absolute VMD, with 1.5 times higher VMD in 
women in the highest, relative to those in the lowest, BMI category (58.4 cm³ [95% CI 57.4 
cm³–59.5 cm³] versus 37.9 cm³ [95% CI 37.1 cm³–38.8 cm³]). Both percent and absolute 
VMD were lower in postmenopausal compared to premenopausal women, and decreased with 
increasing age. Women who reported a family history of breast cancer had slightly higher 
percent and absolute VMD than women with no family history.   
Table 3 shows mean percent and absolute VMD by age at menarche, age at first birth, 
age at menopause, education, height and number of pregnancies. We found increasing percent 
and absolute VMD with increasing age at menarche, increasing age at first birth, increasing 
age at menopause, and with increasing educational level. Both percent and absolute VMD 
decreased with increasing number of pregnancies. We observed a weak positive association 
between height and percent VMD in unadjusted (i.e. adjusted for age only) analyses, but this 
association diminished upon adjustment for BMI and the other covariates. The positive 
association between height and absolute VMD, however, persisted after adjustment. 
Table 4 shows mean percent and absolute VMD by duration of breastfeeding, age at 
start of oral contraceptives and duration of oral contraceptives, and use and duration of 
postmenopausal hormone therapy. We found increasing percent and absolute VMD with 
increasing duration of breastfeeding, in current postmenopausal hormone therapy users, and 
with duration of postmenopausal hormone therapy. Neither percent nor absolute VMD were 
affected by use of oral contraceptives (p for trend>0.38). 
Table 5 shows mean percent and absolute VMD by selected lifestyle factors, and both 
percent and absolute VMD were slightly lower among current smokers. A dose-response 
positive association was observed between amount of alcohol consumed and percent and 
absolute VMD. There was an inverse association between physical activity and absolute 
VMD, and increased percent VMD in women exercising more than six hours a week.  
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Although most of these associations were highly significant (p<0.001), the magnitude 
of the effect was modest. We found differences in percent and absolute VMD between the 
lowest and highest exposure categories (with an absolute magnitude of ≥1.0% and ≥5.0 cm³, 
respectively) for age, BMI, number of pregnancies, menopausal status, and duration of 
breastfeeding.  
The results were essentially unchanged when the analyses were additionally adjusted 
for age at menarche, age at first birth, duration of breastfeeding in months, use of 
postmenopausal hormone therapy, and family history of breast cancer. We mutually adjusted 
for smoking, alcohol, and physical activity in analyses with those variables, and results were 
unchanged. 
When examining the association between age and menopausal status with percent and 
absolute VMD, we found a larger difference in VMD per five-year increase in age at 
screening in pre/perimenopausal women compared to postmenopausal women, that this 
difference was present in women of different risk factor levels, and that this difference was 
modified by BMI, postmenopausal hormone therapy and family history of breast cancer 
(Supplementary Table 1).  
Figure 1 shows associations between age and menopausal status with VMD, stratified 
by BMI, postmenopausal hormone therapy and family history of breast cancer. We found the 
largest difference in percent VMD among postmenopausal women with a BMI<25 kg/m and 
no apparent difference in postmenopausal women with a BMI≥30 kg/m² (p-int<0.0001). 
Associations stratified by use of postmenopausal hormone therapy showed a larger difference 
in percent and absolute VMD with increasing age at screening in never users of 
postmenopausal hormone therapy, compared to past and current users (p-int<0.0001), and 
associations stratified by a family history of breast cancer showed that premenopausal women 
with a family history had a larger difference in absolute VMD with age at screening compared 
to premenopausal women with no family history (p-int=0.054).  
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Further examination of VMD with age using cubic spline regression revealed that the 
non-linear model was not a better fit than the linear model in pre/perimenopausal women 
(percent VMD p=0.792 and absolute VMD p=0.963), however there could be a plateauing of 
VMD in postmenopausal women (percent VMD p<0.0001 and absolute VMD p=0.008). For 
these women, the overall VMD-age associations from Supplementary Figure 1 were modestly 
stronger when we excluded women over 65 years (the coefficient for percent VMD changed 
from -0.08 to -0.09 and for absolute VMD from -0.03 to -0.04).  
 
 
Discussion 
 
We found associations between VMD and several breast cancer risk factors in this largely 
postmenopausal cohort, with the strongest associations between BMI and percent and 
absolute VMD. BMI was positively associated with absolute VMD, but inversely associated 
with percent VMD. Further, we found modest differences in percent and absolute VMD 
between the highest and lowest category of the following risk factors; age, height (only 
absolute), number of pregnancies, menopausal status, and duration of breastfeeding. Lower 
percent and absolute VMD were observed with increasing age at screening, and with being 
postmenopausal compared to pre/perimenopausal. The inverse association with age appears 
modified not only by menopausal status at baseline, but also by BMI (percent VMD in 
postmenopausal women), use of postmenopausal hormone therapy, and family history of 
breast cancer (absolute VMD in premenopausal women).  
When comparing the observed associations between VMD and breast cancer risk 
factors with results from area-based mammographic density studies (12, 17, 37-44), the 
observed direction of the associations between VMD and breast cancer risk factors were 
mostly similar. An exception was BMI, which has been inversely associated with 
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mammographic density in area-based studies. This study found BMI to be inversely 
associated with percent VMD, but positively associated with absolute VMD, consistent with 
other studies using volumetric methods (16-18, 45, 46). We have no strong explanation for 
the difference between volumetric and area-based methods when it comes to BMI except that 
the two methods capture different variations in breast tissue composition, and that volumetric 
methods may be more accurate (46).  
BMI is associated with breast size and amount of fatty tissue in the breast. It is 
expected that women with high BMI often have larger breasts and larger amount of fatty 
tissue, i.e. they have lower percent VMD, however, they also often have more breast tissue in 
total, and more dense volume, and therefore higher absolute VMD compared to women with 
smaller breasts (18, 47). It is not clear whether percent or absolute VMD is the most important 
measure biologically (48), and which measure to use, especially in models including BMI, 
have implications for the consistency of the estimates. Since BMI is inversely associated with 
percent VMD, it can reduce the overall effect whenever BMI is positively associated with the 
exposure, it is therefore important to adjust for BMI especially in analyses with percent VMD. 
The underlying distribution of VMD is more left-skewed than the distribution of area-
based mammographic density measures, with a smaller range of possible values in VMD. 
When comparing the differences across categories of age and BMI with a previous area-based 
study in the same population (41), results suggest that the difference across categories is 2.5-4 
times lower for VMD. This implies that a difference of 1.5-2% in VMD is similar to a 
clinically relevant 5% difference in area-based density. While area-based methods assume 
that dark areas of a mammogram are composed of fat, and each pixel in the mammogram is 
either dense or non-dense, volumetric methods estimate the relative amount of dense tissue in 
each individual pixel. A recent validation study comparing VMD to MRI indicated that 
Volpara may slightly underestimate the true density as measured by MRI (49). However, 
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although the associations may be weaker, the overall associations and the usually accepted 
determinants of mammographic density seems to be similar for VMD.  
Breastfeeding is associated with reduced breast cancer risk (50), but not in a case-
control study nested within the same screening population as the present study (51). This 
could be because the protective effect of breastfeeding is time-limited, and may be seen 
predominately in younger women (52, 53). Consequently, the positive association we 
observed between breast feeding and VMD should not be given too much significance and 
may simply reflect the age of our cohort or be a chance finding. Physical activity protects 
against breast cancer (54), and we found an inverse association between physical activity and 
absolute VMD. The positive association between percent VMD and exercising more than six 
hours a week may reflect residual confounding by BMI.  
It is well-known that women experience both a reduction in dense tissue and an 
increase in fatty tissue with increasing age (29). We found lower percent and absolute VMD 
to be associated with older age at screening in both pre/perimenopausal and postmenopausal 
women, where the largest age-associated differences were found in pre/perimenopausal 
women. This may reflect the reduction in circulating sex hormones during the menopausal 
transition (55). Several risk factors that influence breast cancer and mammographic density 
could modify this age-VMD association, through modification of breast cell involution or 
breast tissue composition changes over time (15). We found that the magnitude of the age-
related differences in percent VMD was modified by BMI in postmenopausal women, the 
differences in both percent and absolute VMD by use of postmenopausal hormone therapy, 
and the difference in absolute VMD by family history of breast cancer in pre/perimenopausal 
women. The age-associated differences in percent VMD was smaller among postmenopausal 
women that were overweight and obese than in those with a BMI<25 kg/m². This finding is 
consistent with that of Maskarinec et al. (19). Hormonal or reproductive events could be less 
influential in women with a BMI ≥30 kg/m² whose circulating estrogen levels may be 
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elevated by peripheral conversion in adipose tissue of androgens produced by the supra-renal 
glands (39). We found larger age-associated differences in VMD in never users of 
postmenopausal hormone therapy, compared to current and past users, which has been 
described previously (19, 56). Never users may consist of a unique group of women because 
they have not experienced menopausal symptoms (57). The larger age-associated difference 
in absolute VMD by family history of breast cancer in pre/perimenopausal women could 
perhaps reflect genetic risk factors that are mediated by hormones linked to the menopausal 
transition (58).  
 
Strengths and limitations 
Strengths of our study include detailed information on breast cancer risk factors and VMD 
measures using a fully automated volumetric method. Another strength is the population-
based screening cohort and its very large size, albeit the latter means that differences of small 
magnitude can reach statistical significance even if they are of no clinical significance. We 
therefore considered the absolute magnitude of the observed differences. 
The most important limitation of the study is that it is cross-sectional rather than 
longitudinal. The observed age- and menopausal differences may reflect true declines with 
age and menopausal status, but also differences in density across different cohorts of women, 
without disentangling between the two. Another limitation is that Volpara tends to 
underestimate VMD in very dense breasts (49, 59, 60). The selection of internal reference is 
more complex in dense breasts, i.e. finding an area of the breast that is entirely fat, which 
affects the calibration of fatty tissue attenuation. This misclassification, which is likely to be 
non-differential, could have underestimated the magnitude of exposure-VMD associations in 
our data. Self-reported height and weight measures could lead to misclassification and 
inability in adjusting completely for the confounding effect of BMI. However, a recent study 
found that women attending BreastScreen Norway consistently reported weight and height 
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within one kg/cm (31). The cohort included women between 49 and 71 years of age. A wider 
age range would have been beneficial, especially the inclusion of women of younger ages.  
 
Conclusions 
 
This large study has added important knowledge concerning VMD; 1) volumetric and area-
based mammographic density share similar correlates, 2) the strongest association was found 
for BMI, with the direction of the association differing for percent (negative association) and 
absolute (positive association) VMD, 3) percent and absolute VMD were inversely associated 
with age at screening in both pre/perimenopausal and postmenopausal women; however, 
larger age-associated differences were observed among pre/perimenopausal women, and 4) 
the magnitude of the age-associated differences in percent VMD was modified by BMI in 
postmenopausal women, the differences in both percent and absolute VMD by use of 
postmenopausal hormone therapy, and the difference in absolute VMD by family history of 
breast cancer in pre/perimenopausal women. Since VMD methods are becoming widely 
available in screening and clinical settings, the association between VMD measures and 
breast cancer risk factors should be investigated further in longitudinal studies. 
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Table 1 Characteristics of the study population (N=46 234) 
Characteristic Mean (SD), unless stated Range 
Age at mammography, years 56.1 (5.6) 49.1-71.0 
Height, cm 166.3 (5.7) 130-198 
BMI, kg/m² 25.6 (4.2) 10.0-54.5 
Age at menarche, years 13.3 (1.4) 9-18 
Number of pregnancies 2.6 (1.6) 0-20 
Age at first birth, years 23.6 (4.6) 13-50 
Duration breastfeeding, months 16.9 (12.9) 0-80 
Age at menopause, years 49.1 (4.7) 25-67 
Age at start of oral contraceptives, years 21.6 (5.2) 11-50 
University bachelor/master 36.3%  
Nulliparous 9.3%  
Post-menopausal 73.5%  
Family history of breast cancer 23.3%  
Hormone therapy use ever 33.5%  
Current smokers 23.1%  
Alcohol consumers (≥1 glass per week) 79.2%  
Inactive 11.5%  
Mammographic measures   
Percent VMD 7.2 (4.5) 1.5-41.6 
Percent VMD, median 5.8  
Absolute VMD cm³ 49.3 (25.2) 5.7-334.9 
Absolute VMD cm³, median 43.0  
Percent VMD, left CC view 7.5 (4.9) 1.4-51.6 
Percent VMD, left CC view, median 5.9  
Percent VMD, left MLO view 6.9 (4.3) 1.1-50.8 
Percent VMD, left MLO view, median 5.6  
Absolute VMD, left CC view 46.6 (25.8) 5.1-504.6 
Absolute VMD, left CC view, median 40.1  
Absolute VMD, left MLO view 51.6 (28.1) 3.6-464.0 
Absolute VMD, left MLO view, median 44.8  
SD, standard deviation; BMI, body mass index, VMD; volumetric mammographic density, CC; 
craniocaudal, MLO; mediolateral oblique 
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Table 2 Unadjusted and adjusted mean (95% CI) percent and absolute VMD by selected breast 
cancer risk factors (n=46 234) 
  Percent VMD Absolute VMD 
 
 
 
n 
Age-
adjusted
a 
Multiadjusted
b 
(95% CI) 
Age-
adjusted
a 
Multiadjusted
b 
(95% CI) 
Age      
 <50 1760 9.1 8.2 (8.0-8.4) 56.9 52.5 (51.3-53.8) 
 50 5365 8.8 8.1 (8.0-8.2) 56.1 52.7 (52.0-53.5) 
 51 6113 8.2 7.7 (7.6-7.8) 52.8 50.5 (49.9-51.2) 
 52-53 6880 7.9 7.7 (7.6-7.8) 51.4 50.7 (50.1-51.3) 
 54-55 4940 7.1 7.2 (7.1-7.3) 48.3 49.2 (48.5-49.8) 
 56-57 4482 6.7 7.0 (6.9-7.1) 46.5 47.8 (47.2-48.5) 
 58-59 3777 6.5 6.8 (6.7-6.9) 45.9 47.4 (46.7-48.1) 
 60-61 3480 6.2 6.5 (6.4-6.7) 45.5 47.1 (46.4-47.9) 
 62-63 2991 6.0 6.5 (6.4-6.6) 45.1 46.7 (45.9-47.5) 
 64-65 2591 5.9 6.3 (6.2-6.5) 45.2 47.2 (46.3-48.3) 
 66-67 2114 5.7 6.1 (6.0-6.3) 44.1 46.5 (45.6-47.4) 
 ≥68 1741 5.7 6.1 (5.9-6.3) 43.1 45.5 (44.6-46.4) 
p-trend  <0.0001 <0.0001 <0.0001 <0.0001 
BMI (kg/m²)     
 <20 2284 13.0 12.9 (12.7-13.2) 38.1 37.9 (37.1-38.8) 
 20 2583 11.2 11.1 (10.9-11.3) 42.4 42.2 (41.3-43.0) 
 21 3770 9.8 9.7 (9.6-9.9) 44.4 44.3 (43.5-45.1) 
 22 4738 8.8 8.8 (8.6-8.9) 46.9 46.9 (46.2-47.6) 
 23 5038 7.9 7.9 (7.7-8.0) 48.2 48.3 (47.6-49.0) 
 24 5352 7.2 7.2 (7.1-7.3) 49.2 49.3 (48.6-50.0) 
 25 4515 6.4 6.4 (6.3-6.5) 50.1 50.3 (49.5-51.0) 
 26 3863 5.9 5.9 (5.8-6.0) 50.5 50.8 (50.1-51.6) 
 27 3138 5.6 5.6 (5.5-5.7) 52.9 53.0 (52.1-53.9) 
 28-30 6270 4.9 4.9 (4.9-5.0) 53.0 52.9 (52.3-53.5) 
 31-32 2190 4.3 4.3 (4.2-4.4) 54.3 54.3 (53.2-55.3) 
 ≥33 2493 3.9 3.9 (3.9-4.0) 58.9 58.4 (57.4-59.5) 
p-trend  <0.0001 <0.0001 <0.0001 <0.0001 
Menopausal status     
 Pre- 7602 8.3 8.3 (8.2-8.4) 56.1 56.3 (55.6-57.1) 
 Peri- 4660 7.4 7.6 (7.4-7.7) 51.8 51.5 (50.7-52.3) 
 Post- 33972 6.9 6.9 (6.9-7.0) 47.2 47.2 (47.0-47.5) 
p-trend  <0.0001 <0.0001 <0.0001 <0.0001 
Family history of BC     
 No 34456 7.2 7.2 (7.1-7.2) 48.8 48.9 (48.6-49.1) 
 Yes 10447 7.5 7.4 (7.3-7.5) 50.8 50.7 (50.2-51.2) 
p-trend  <0.0001 <0.0001 <0.0001 <0.0001 
aAdjusted for age at mammography 
bAdditionally adjusted for BMI, education, menopausal status, and pregnancies 
VMD; volumetric mammographic density, CI; confidence interval, sec; secondary, BMI; body mass 
index, BC; breast cancer 
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Table 3 Unadjusted and adjusted mean (95% CI) percent and absolute VMD by selected breast cancer 
risk factors (n=46 234) 
Percent VMD Absolute VMD 
n 
Age-
adjusted
a 
Multiadjusted
b
(95% CI) 
Age-
adjusted
a 
Multiadjusted
b
(95% CI) 
Age at menarche (years) 
9-12 13136 6.7 7.1 (7.0-7.1) 49.0 48.1 (47.7-48.5) 
13 12571 7.2 7.2 (7.2-7.3) 49.5 49.4 (49.0-49.9) 
14 10844 7.5 7.3 (7.2-7.4) 49.2 49.7 (49.2-50.1) 
15-18 7831 7.8 7.4 (7.3-7.5) 49.3 50.2 (49.7-50.8) 
p-trend <0.0001 <0.0001 0.526 <0.0001 
Age at first birth
c 
13-20 11380 6.6 6.9 (6.8-7.0) 47.0 47.5 (47.1-48.0) 
21-22 7445 6.9 7.0 (7.0-7.1) 47.4 47.9 (47.3-48.4) 
23-25 10473 7.3 7.2 (7.2-7.3) 48.7 48.9 (48.4-49.4) 
26-30 8395 7.7 7.4 (7.3-7.4) 49.7 49.3 (48.7-49.8) 
31-50 3260 7.9 7.5 (7.3-7.6) 53.3 51.2 (50.2-52.1) 
p-trend <0.0001 <0.0001 <0.0001 <0.0001 
Age of menopause (years)
d
<47 7164 6.4 6.5 (6.4-6.6) 45.7 45.4 (44.9-45.9) 
47-49 7025 6.7 6.6 (6.5-6.7) 45.5 45.7 (45.2-46.2) 
50-52 11658 6.8 6.8 (6.7-6.8) 46.6 46.8 (46.4-47.2) 
>52 6393 6.8 6.9 (6.8-7.0) 48.5 48.3 (47.7-48.9) 
p-trend <0.0001 <0.0001 <0.0001 <0.0001 
Education
Lower sec. 9302 6.7 6.9 (6.8-7.0) 47.8 47.9 (47.4-48.4) 
Upper sec. 20146 7.0 7.1 (7.0-7.1) 48.9 48.8 (48.5-49.2) 
Bachelor 10331 7.7 7.5 (7.4-7.6) 50.2 50.3 (49.8-50.7) 
Master 6455 8.1 7.7 (7.6-7.8) 50.7 50.7 (50.1-51.4) 
p-trend <0.0001 <0.0001 <0.0001 <0.0001 
Height
<159 3844 7.0 7.3 (7.2-7.4) 46.7 46.2 (45.4-46.9) 
160-164 12934 7.1 7.2 (7.1-7.3) 47.7 47.8 (47.4-48.2) 
165-169 15038 7.3 7.2 (7.2-7.3) 49.7 49.8 (49.4-50.2) 
170-174 10025 7.4 7.3 (7.2-7.4) 50.7 50.6 (50.1-51.1) 
175-179 2945 7.5 7.3 (7.1-7.4) 52.5 52.5 (51.5-53.4) 
≥180 524 7.2 7.1 (6.7-7.4) 53.1 52.7 (50.3-55.1) 
p-trend <0.0001 0.707 <0.0001 <0.0001 
No of pregnancies
Never 4287 7.9 8.0 (7.9-8.2) 55.5 55.3 (54.5-56.2) 
1 4065 7.6 7.6 (7.5-7.7) 53.3 53.5 (52.6-54.3) 
2 17704 7.4 7.3 (7.3-7.4) 49.7 49.8 (49.4-50.2) 
3 14251 7.0 7.0 (6.9-7.0) 47.2 47.2 (46.8-47.5) 
≥4 5927 6.7 6.8 (6.7-6.9) 45.5 45.3 (44.7-45.8) 
p-trend <0.0001 <0.0001 <0.0001 <0.0001 
a Adjusted for age at mammography 
b  Additionally adjusted for BMI, education, menopausal status, and pregnancies 
c  Excluding nulliparous women 
d Excluding pre/perimenopausal women 
VMD; volumetric mammographic density, CI; confidence interval 
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Table 4 Unadjusted and adjusted mean (95% CI) percent and absolute VMD by selected 
breast cancer risk factors (n=46 234) 
Percent VMD Absolute VMD 
n 
Age-
adjusted
a 
Multi-
adjusted
b 
(95% CI) 
Age-
adjusted
a 
Multi- 
Adjusted
b 
(95% CI) 
Duration breastfeeding (months) 
Parous no 
breastfeeding 
37 6.8 6.2 (5.2-7.2) 44.6 44.3 (40.1-48.6) 
1-6 8455 6.9 6.9 (6.8-7.0) 48.1 45.9 (45.3-46.4) 
7-12 8996 7.1 7.1 (7.0-7.2) 49.0 47.7 (47.1-48.2) 
13-20 8642 7.5 7.4 (7.3-7.5) 49.5 49.2 (48.7-49.7) 
21-30 6537 7.5 7.5 (7.4-7.6) 49.7 50.5 (49.8-51.1) 
>30 4321 7.5 7.7 (7.5-7.8) 48.4 50.5 (49.7-51.3) 
p-trend <0.0001 <0.0001 0.025 <0.0001 
Age at start of OC (years)
c 
<19 6769 7.1 7.2 (7.1-7.3) 49.6 49.2 (48.6-49.8) 
19-20 5778 7.4 7.2 (7.1-7.3) 49.5 49.5 (48.8-50.1) 
21-24 6118 7.5 7.3 (7.2-7.4) 49.3 49.4 (48.8-50.1) 
>24 5179 7.4 7.3 (7.2-7.4) 48.8 48.8 (48.1-49.5) 
p-trend 0.001 0.068 0.113 0.395 
Duration of OC (years)
Never users 19855 7.2 7.2 (7.2-7.3) 49.2 49.3 (48.9-49.6) 
<2 3498 7.3 7.3 (7.1-7.4) 49.3 49.4 (48.6-50.3) 
2-5 8269 7.3 7.3 (7.2-7.4) 49.1 49.2 (48.6-49.7) 
6-10 5378 7.3 7.3 (7.2-7.4) 49.6 49.4 (48.7-50.1) 
>10 4803 7.4 7.2 (7.1-7.3) 49.1 48.8 (48.1-49.5) 
p-trend 0.001 0.916 0.755 0.379 
Postmenopausal hormone
therapy
Never 26774 7.2 7.3 (7.2-7.3) 49.7 49.5 (49.2-49.8) 
Past 6588 7.1 7.2 (7.1-7.3) 48.5 48.9 (48.3-49.5) 
Estrogen current 3986 7.6 7.5 (7.3-7.6) 49.2 49.9 (49.1-50.7) 
EP current 2938 8.1 7.8 (7.6-7.9) 52.4 52.4 (51.3-53.4) 
p-trend <0.0001 <0.0001 0.005 <0.0001 
Duration of EP therapy (years)
Never 26774 7.3 7.3 (7.3-7.4) 49.9 49.7 (49.4-50.0) 
<3 2629 7.3 7.4 (7.2-7.5) 49.0 49.7 (48.6-50.7) 
3-5 2188 7.7 7.6 (7.4-7.7) 50.0 50.5 (49.4-51.6) 
6-10 1640 7.8 7.6 (7.4-7.8) 49.3 49.8 (48.6-51.0) 
>10 2002 8.2 7.8 (7.6-8.0) 50.5 50.9 (49.7-52.0) 
p-trend <0.0001 <0.0001 0.882 0.061 
aAdjusted for age at mammography 
bAdditionally adjusted for BMI, education, menopausal status, and pregnancies 
c Excluding women who never used oral contraceptives 
VMD; volumetric mammographic density, CI; confidence interval, OC; oral contraceptives, EP; 
estrogen and progestin 
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Table 5 Unadjusted and adjusted mean (95% CI) percent and absolute VMD by smoking, 
alcohol use, and physical activity level (n=46 234) 
Percent VMD Absolute VMD 
n 
Age-
adjusted
a 
Multiadjusted
b
(95% CI) 
Age-
adjusted
a 
Multiadjusted
b
(95% CI) 
Smoking 
Never 19780 7.4 7.3 (7.3-7.4) 49.9 49.8 (49.4-50.1) 
Former 14741 7.1 7.3 (7.2-7.3) 50.5 49.9 (49.5-50.3) 
Current 10377 7.2 7.0 (7.0-7.1) 46.3 47.2 (46.8-47.7) 
p-trend 0.055 <0.0001 <0.0001 <0.0001 
Alcohol
Never drinkers 9177 6.9 7.3 (7.2-7.4) 49.1 49.1 (48.5-49.6) 
1 glass/week 10929 7.0 7.1 (7.1-7.2) 49.0 48.9 (48.4-49.3) 
2 glass/week 8563 7.3 7.2 (7.1-7.3) 48.5 48.8 (48.3-49.3) 
3-4 glasses week 10094 7.5 7.3 (7.2-7.4) 49.8 49.8 (49.3-50.3) 
5-6 glasses week 3389 7.7 7.3 (7.2-7.5) 50.4 50.2 (49.4-51.1) 
>6 glasses week 2072 8.2 7.5 (7.4-7.7) 51.6 51.3 (50.1-52.0) 
p-trend <0.0001 0.001 <0.0001 <0.0001 
Physical activity
No exercise 5266 6.5 7.2 (7.0-7.3) 51.2 50.2 (49.5-50.9) 
1-2.5 hours/week 16031 6.9 7.2 (7.1-7.3) 50.1 49.7 (49.4-50.1) 
2.5-4.5 hours/week 15281 7.4 7.3 (7.2-7.4) 48.9 49.0 (48.6-49.4) 
4.5-6 hours/week 8621 7.8 7.2 (7.2-7.3) 47.5 48.4 (47.9-49.0) 
6+ hours/week 664 8.3 7.4 (7.1-7.6) 45.0 46.5 (44.9-48.2) 
p-trend <0.0001 0.074 <0.0001 <0.0001 
a
Adjusted for age at mammography 
b
Additionally adjusted for BMI, education, menopausal status, and pregnancies. 
VMD; volumetric mammographic density, CI; confidence interval 
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Figure 1 Associations of percent and absolute volumetric mammographic density with age (in 
2-year age groups) and menopausal status, overall and by subgroups. All models are adjusted
for body mass index, education, and number of pregnancies. Premenopausal women above
the age of 55 years are excluded. Pre, premenopausal and perimenopausal women; post,
postmenopausal women; coef, coefficient; p-int, p for interaction. *Rate of decline per a 5-
year increment in age. **Interaction between age and the exposure.
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Figure 1 
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